

Fracture Table vs. Lateral Positioning for Intramedullary Fixation of Femur Fractures (The FLiP Study): A protocol for a pilot randomized controlled trial

Daniel Axelrod Corresp., 1, Herman Johal 1, Kim Madden 1, Francesc Marcano 2, Carlos Prada 2

Corresponding Author: Daniel Axelrod Email address: daniel.axelrod@medportal.ca

Background: Femoral Shaft fractures are devastating and life threatening injuries. Femoral shaft fractures are most commonly treated with intramedullary fixation. Malrotation of the injured limb after fixation is a common and significant complication following femoral shaft fractures. During the operation, patients can be positioned either supine or in a lateral position. Additionally, patients can be placed on a standard radiolucent operating room table, or placed on a fracture table with traction statically applied to the operative limb throughout the case. Previous case series and cohort studies have shown equivalence between study groups, but choice between positioning options remains controversial. Methods: This represents a protocol for a randomized controlled pilot trial. We will be compared lateral positioning with use of manual traction to supine positioning with use of a fracture table. Primary outcomes will be in assessment for feasibility for a future full scale randomized trial, including evaluating patient recruitment, patient compliance with followup, contamination between treatment arms and others. Results: The primary outcome will be feasibility for a future trial. Secondary outcomes will include malrotation as measured through intraoperative radiographs, postoperative computed tomography scans and gait analysis at 6 months.

¹ McMaster University, Hamilton, Canada

 $^{^{\}mathbf{2}}$ Centre for Evidence Based Orthopedics, McMaster University, Hamilton, Canada



Fracture Table vs. Lateral Positioning for Intramedullary Fixation of Femur Fractures (The FLiP
Study): A protocol for a pilot randomized controlled trial
Daniel Axelrod, Carlos Prada, Herman Johal, Kim Madden
Centre for Evidence-Based Orthopaedics, McMaster University, Hamilton Ontario Canada
Corresponding Author:
Daniel Axelrod
237 Barton Street E, Hamilton, On, L8L 2X2
Email address: daniel.axelrod@medportal.ca
Abstract
Background: Femoral Shaft fractures are devastating and life threatening injuries. Femoral shaft
fractures are most commonly treated with intramedullary fixation. Malrotation of the injured
limb after fixation is a common and significant complication following femoral shaft fractures.
During the operation, patients can be positioned either supine or in a lateral position.
Additionally, patients can be placed on a standard radiolucent operating room table, or placed on
a fracture table with traction statically applied to the operative limb throughout the case.
Previous case series and cohort studies have shown equivalence between study groups, but
choice between positioning options remains controversial.
Methods: This represents a protocol for a randomized controlled pilot trial. We will be compared
lateral positioning with use of manual traction to supine positioning with use of a fracture table.
Primary outcomes will be in assessment for feasibility for a future full scale randomized trial,
including evaluating patient recruitment, patient compliance with followup, contamination
between treatment arms and others.
Results: The primary outcome will be feasibility for a future trial. Secondary outcomes will
include malrotation as measured through intraoperative radiographs, postoperative computed
tomography scans and gait analysis at 6 months.
Introduction

Femoral shaft fractures are common and severe injuries that typically occur alongside other complex, high-energy injuries in the poly-traumatized patient. Femur fractures can yield extensive bleeding and muscle injury of the thigh, and have a high worldwide burden; occurring at a rate between 14 and 42.5 /100,000 person years, with approximately 1 in 10 road traffic accidents worldwide involving a femoral shaft fracture treated by surgery¹. Additionally, there is a significant disparity of burden for diaphyseal femur fractures, with 91% occurring in lower middle class income countries, with the majority affecting younger males.²

To help mitigate the effects of ongoing blood-loss, worsening inflammation and pain from the unstable fracture ends, femoral shaft fractures require urgent management using either an early total-care or damage-control orthopaedics approach^{3,4,5}. Associated injuries, markers of resuscitation, and overall patient stability guide operative decision making on timing of surgical intervention⁶. Definitive internal fixation using reamed, locked intramedullary nailing (IMN) has become the standard of care in the adequately resuscitated patient⁷ as it provides fracture stability while facilitating nursing care and patient mobilization^{8,9}. Multiple femoral IMN techniques exist, however most femoral shaft fractures can be treated with an antegrade nail using either supine (fracture table) or lateral (free-leg drape) positioning^{10,11}. Fracture pattern, patient characteristics, associated injuries, hospital-resources, availability of assistants and surgeon preference may all play a role in determining which positioning option is chosen. There are advantages and disadvantages to each, and little clinical evidence exists to aid in decision-making.

This research group completed a systematic review of the literature on patient positioning during antegrade nailing of femur fractures in the last year (Journal # OTAI-18-00048). The review revealed only three non-prospective studies on this specific topic, 12,13. This clearly leaves much uncertainty surrounding optimal patient positioning during the definitive treatment of these critical injuries.

For antegrade IMN, supine positioning is most commonly accompanied by a fracture (or traction) table. This surgical table secures the injured extremity and maintains it in a set position throughout the procedure using an adjustable amount of mechanical traction applied though a boot or skeletal traction pin, while using posts and straps to provide counter traction. While this may do an excellent job at obtaining length, it may be easy to mal-reduce comminuted fractures if keen attention is not paid to other anatomic reference points that help restore alignment and rotation¹⁴. This is vital, as the main reason for malpractice litigation following a femoral shaft fracture is failing to restore anatomic length, alignment and rotation¹⁵. While the traction table may be a useful tool, it can easily over-power the patients own resting soft tissue tension, and

lead to mal-reduction of the fracture. The most challenging intraoperative assessment is that of femoral rotation¹⁶. Numerous tools are used, including cortical width, cortical diameter, lesser trochanter profile and others¹⁷. The most reliable technique described in recent papers is the lesser trochanter profile, but it requires a true anteroposterior view of the pelvis, which can be challenging to obtain with the fracture table in situ.

In addition to this, numerous issues may arise secondary to prolonged procedures and application of traction. FlierI described a host of potential issues: perineal skin and soft tissue compromise from using a metal post between the patients leg, neurologic impairment of the non affected leg with either a femoral or peroneal nerve palsy, and iatrogenic compartment syndrome of the non affected extremity¹⁸. All of these can occur at a variable rate, but are serious and potentially avoidable complications. Lastly, not every hospital has easy access to a fracture table. They are expensive, routinely over \$200,000 including all orthopaedic extensions¹⁹, and are specialized tables designed exclusively for orthopaedic trauma. Fracture tables may not be a feasible or practical piece of equipment for some centers to invest in.

The use of the lateral position for intramedullary nailing has been described for the past thirty years²⁰, though rarely reported on in the literature. Patients who present with femur fractures are often multiply injured trauma patients, and as such surgeons and anaesthesists have been hesitant to place these patients in a lateral decubitus or even a modified lateral position, with a bump under the patients hip, in the past. Their concerns stem from belief that a lateral position can worsen respiratory function and prolong extubation, leading to longer ICU stay, especially in patients who may have had thoracic injuries during their index traumatic event. However results from the most recent cohort studies actually suggest the opposite, that patients treated in the lateral position may have shorter ICU stay and reduced days on a ventilator, adjusting for patient risk in propensity based analyses²¹.

Furthermore, part of the reluctance to use the lateral position may be due to lack of surgeon experience and comfort. The commonly used technique of using the fracture table for femoral neck fractures and intertrochanteric hip fractures is easily applied for fixation of femoral shaft fractures. Converting the patient position to the lateral position yields a different radiologic perspective throughout the case and may represent a challenge for surgeons who are not accustomed to interpreting intraoperative fluoroscopic images in this position.

In order to ascertain surgeon preferences, we conducted both a province wide survey through the Ontario orthopaedic association (OOA), Canadian Orthopaedic association (COA) and an international survey amongst members of the AO Trauma group. The 197 respondents clearly showed the disparity and disagreement amongst standard of care for these significant



108

109

110 111

112

113

116

117

120

121

injuries. Sixty four (64) percent of surgeons surveyed in the AOT group said they prefer either sloppy lateral or direct lateral for antegrade fixation of femur fractures (AFFF). Interestingly, they reported that their colleagues, perhaps not members of the AOT, choose supine on a fracture table for AFFF more than 65% of the time. Commonly, surgeons reported that lack of comfort and expertise (48.2%) were reasons for themselves not choosing a lateral position for AFFF. Furthermore, the respondents endorsed the significant complication risk of fracture table use, with 82% of respondents answering that they witness a traction table related injury at a rate 114 greater than 1%. Lastly, 60% of respondents were interested in being part of this clinical trial, 115 indicating the interest in and controversy surrounding this topic. This topic was also presented at the Orthopaedic Trauma Association meeting (OTA), in the Canadian Orthopaedic Trauma Society (COTS) subgroup meeting. Again, there was substantial interest in this topic, and 118 suggestions from that meeting were incorporated as modifications to the study protocol. 119 Respondents reported that the main benefits of lateral positioning were ease of control of the fracture fragments throughout the entire procedure, as the leg is not under constant traction or draped outside of the sterile field. This finding has been reproduced when use of manual 122 traction in a supine position has been compared to fracture table in a prospective randomized 123 study, but never objectively assessed with a laterally positioned patient.²² This allows the 124 fracture fragments to be freely manipulated and muscles to find their resting tension, which may help better restore overall alignment. Furthermore, the use of the lateral position does not yield 126 any traction related complications.

127 128

129

125

Materials & Methods

130 131

STUDY DESIGN

133 134

135

136

137

138

139

132

Design Overview and Rationale

This will be a 2-group parallel-randomized controlled pilot trial. This design will allow us to have direct evidence comparing the efficacy and safety of the two surgical interventions. We require a pilot trial prior to a large multi-centre definitive trial to identify any issues with the methodology, study process, enrollment, data collection, and participant retention and to make any necessary changes prior to large-scale implementation of a definitive trial.

140 141

Setting



142 The Centre for Evidence-Based Orthopaedics (CEO) at McMaster University in Hamilton 143 Ontario will be the Methods Centre for this trial. The CEO has conducted several of the largest 144 multinational trials and observational studies in orthopaedics to date including the 1319 patient 145 SPRINT trial, the 2447 patient FLOW trial, the 2945 patient PRAISE study, the 1108 patient 146 FAITH trial, the 1501 patient HEALTH trial, and the ongoing INORMUS study that has enrolled 147 more than 30,000 patients to date. The CEO has the infrastructure to successfully conduct large 148 multicentre studies including research coordinators, data managers, statisticians/data analysts, 149 a large network of investigators, and available hardware, software, and office space. 150 Additionally, McMaster University is widely known for innovations in evidence-based medicine, 151 clinical epidemiology, biostatistics, and health research methodology. Our interdisciplinary 152 research team is comprised of experts in orthopaedic surgery, anaesthesia and pain 153 management, health research methodology, and biostatistics, and includes patient advocates. 154 155 Pilot sites will include the Hamilton General Hospital in Hamilton, Ontario, and possibly other 156 academic centres affiliated with the Canadian Orthopaedic Trauma Society (COTS). This will be 157 determined by funding available at respective local centres. Hamilton General Hospital is a 158 Level One trauma centre serving all municipalities east of Oakville in the greater Toronto area. 159 as well as throughout the southern part of the golden horseshoe including Hamilton, Haldimand-160 Norfolk, Niagara, Brantford, and Burlington. This hospital treats between 6-10 mid shaft femur 161 fractures per month (determined through internal database review). 162 163 Eligibility 164 Inclusion Criteria 165 Adult (18+) 166 Mid shaft (Diaphyseal) femur fracture appropriate for antegrade fixation 167 Surgeon agreement for participation in study Ability to obtain perioperative imaging (CT scans) 168 169 Provision of informed consent 170 171 Exclusion criteria 172 Inability to provide informed consent (e.g. cognitive disability, language barrier) 173 Age > 65 174 **Bilateral Femoral Fractures**

Inability or lack of willingness to attend follow up



- Ipsilateral tibial fracture
- Ipsilateral femoral neck fracture
- Ipsilateral acetabular fracture
- Pregnant or breastfeeding
- Contraindications to CT imaging including impaired kidney/liver function, or lack of timely
 availability
- Periprosthetic fracture
- Pathologic fracture
- Significant delirium or dementia

187

189

200

201

Screening and Consent Process

188 Enrolling surgeons or authorized research personnel will identify all potentially eligible patients

who have diaphyseal femur fractures. Similar to the A-Prep study²³, we will use cluster

randomization. This type of randomization implies that the patient will not be individually

191 randomized but the institution would be. A positioning would be randomized at the first month of

initiation and all patients with this injury will be operated using that position. The position will

alternate on a monthly basis. All patients matching study criteria will undergo surgery either in

194 lateral or supine positioning based on study month.

195 This allows for the patient to be approach for participation postoperatively. Patients will be

196 approached after surgery. The trial will be explained to patients with emphasis that there will be

197 no negative implications should they choose not to be involved. A standardized consent form

198 will be provided to patients which will be signed and stored securely by the research

199 coordinator. As part of the randomization, patients will also be randomized to inclusion or

exclusion from gait analysis studies at one year, with 20% of patients participating in gait

analysis. This second randomization will be done upon completion of follow up at one year and

202 it would be included in the initial consent form. We will obtain ongoing consent from patients at

203 every follow-up appointment and patients will have the option to withdraw consent. In order to

204 do so, patients may inform their surgeon or any research staff. Patients will be provided with the

205 research coordinator's contact information and may also withdraw consent by contacting the

206 research coordinator directly at any time during the study period. At the 6-month follow up,

207 patients will be notified of the 1-year gait analysis assessment. Consenting procedures will

208 follow local policies and International Council on Harmonization and Good Clinical Practice

209 (ICH-GCP) regulations.



210 211 Interventions 212 Supine Positioning, Fracture Table 213 The supine fracture table group will be positioned supine in the operating room, on a fracture 214 table. The operative leg will be placed in a boot, attached to the traction limb. The non operative 215 leg will either be scisorred away from the operating area in a traction boot (without traction 216 placed), or placed in a stirrup at 90 degrees of hip flexion in hemilithotomy. A central post will be 217 used to prevent patient movement during application of traction, and all bony prominences will 218 be padded. Fluoroscopy will be obtained through standard practices. 219 220 Lateral Positioning, Free drape 221 The lateral positioning group will be placed in lateral position after anaesthetic has been 222 provided. A beanbag will be placed below the patient, and the patient will be safely turned to a 223 lateral position (Figure 1, Figure 2). The beanbag will be inflated, the leg will be prepped, and a 224 free drape will be applied. No traction will be used. Alternatively, some participating sites may 225 use stulberg positioners rather than an inflatable beanbag, based on hospital preference. 226 227 228 Adherence, Contamination, and Crossovers 229 In case of crossovers, patients will be analyzed in the group to which they were randomized 230 (intention-to-treat). 231 232 233 Randomization 234 Following confirmation of eligibility, patients will be enrolled into the study group based on block 235 randomization per site. To ensure there is minimal specialist bias, we will invite all provincial 236 trauma surgeons to a cadaver course focusing on lateral patient positioning for AFFF. If the 237 orthopaedic trauma surgeon on call has not performed at least three operations of antegrade 238 IMN of femur fractures in the last year, or attended a cadaver-based course, then the patient will 239 not be a candidate for the study. 240 241 We will aim for a 1:1 allocation ratio. Figure 1 summarizes the screening and randomization 242 process.






Figure 1: Summary of screening and randomization

245

247

248

249

246 Blinding

Patients will be blinded to the treatment protocol they are randomized to. The surgical team will not be blinded to the randomization. The outcome assessors, in particular the radiologists who assess post operative rotation and alignment of the femur fracture, will be blinded to which group the patients were allocated.

250251252

OUTCOMES

253254

Primary Outcome

- Our primary outcome for the pilot trial is feasibility, including the following:
- 256 Recruitment rate
- Participant retention
- Data completeness
- Treatment compliance

260261

Criteria for feasibility success

- 262 We will consider the pilot study to be a success if we are able to achieve the following:
- Recruitment of 80 % of the calculated 200 patients in two years (with an interval assessment of at least 60 patients within first 8 months)
- Follow-up of at least 90% of patients at 3 months
- At least 80% of questionnaires completed at 3 months

267268

Secondary Outcomes



- Length, alignment and rotation of femur measured immediately post operatively through
 bilateral computed tomography scans by blinded personnel.
 - Functional gait abnormalities as measured by gait analysis at one year
- Walking/Gait ability as measured by timed up and go test at 6 weeks, 3 months post surgery
- Pain at 2 weeks, 6 weeks, and 3 months post-surgery. Both pain in the operative leg,
 and generalized assessment of pain will be included.
 - Range of motion 2 weeks, 6 weeks, and 3 months post-surgery
 - Euroquol score at 3 and 6 months post operatively
 - Satisfaction with pain control at 3 months post-surgery
 - Systemic and local adverse events up to 3 months post-surgery including infection, need for revision, and need for hospital readmission

Measurement of Secondary Outcomes

discussed and recorded as a complication.

283 Length, alignment and Rotation

Immediate (within 48 hours of surgery) post-operative bilateral computer tomography of the operated patients lower extremity will be completed. The radiology team, led by Dr. Mammen, will be involved in this study. The quoted cost per CT scan is \$54 (CAD) per patient. This will be incorporated into the eventual budget. These will be reviewed and reported by a staff radiologist. Outcomes included length discrepancy, internal or external rotation of the femur compared to the longitudinal axis and mal-alignment or mal-reduction of fracture components will be recorded. If significant malrotation is identified, need for reoperation with patient will be

Additionally, the patient group will be assessed by functional assessment through timed up and go testing at 6 week, 3 month and one year follow up. Lastly, patients will undergo gait analysis at one year to compare their gait patterns to matched population controls. Population controls have been collected through the McMaster gait analysis lab during previous studies and data has been de-identified. Patients have previously consented to use their de-identified data for future studies. This will help to elucidate if there are relationships between gait abnormalities and patient positioning, radiologic malrotation or patient satisfaction.

Pain



302	We will use a modified version of the World Health Organization (WHO) definition of persistent
303	post-surgical pain. The modifications are to add a minimum severity of pain. To meet the
304	definition of PPSP, a patient mist experience all of the following:
305	The pain is in the study extremity
306	The pain began after surgery
307	 The pain has persisted for at least three months after surgery
308	 The pain is not better explained by an infection, malignancy, a pre-existing pain
309	condition or any other alternative cause (as judged by the treating surgeon)
310	• The severity of pain must be at least 4 on an 11-point NRS for average pain in the past
311	week
312	
313	
314	Wound Complication
315	We will assess the wound integrity at 2 week, 1 month and 6 month follow up. Any wound
316	dehiscence, or concern with appearance or superficial infection will be documented, as well as
317	requirement to treat with oral or parenteral antibiotics.
318	
319	Satisfaction with pain control
320	We will ask patients to rate their satisfaction with pain control using a 5-point Likert scale with
321	options ranging from "poor" to "excellent".
322	
323	Systemic and local adverse events
324	An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in
325	severity during the course of the study.
326	
327	Study Visits and Timelines
328	Patients will be screened for eligibility and randomized at hospital admission. We will collect
329	study data at the following timepoints:
330	• 2 weeks
331	6 weeks
332	• 3 months
333	• 1 year
334	



All visits after the baseline visit can be completed in-clinic or by telephone with additional information collected from medical records, as needed. **Table 1** presents a summary of study events and measurements at each timepoint.

337338339

335

336

Table 1: Schedule of events

Study event/	Baseline	In Hospital	2 week	6 week	3 month	1
measure	(At	(post operative)	f/u	f/u	f/u	Year
	admission)		(10-18	(35-49	(77-105	
			days)	days)	days)	
Screening	Х					
Consent		X				
Randomization	X					
Demographics and		X				
baseline info						
Pain			Х	Х	Х	Х
Length, Rotation		X				
Adverse events	X	X	Х	Х	Х	Х
Satisfaction			Х	Х	Х	Х
Gait Analysis						Х

340

341

342

345

346

347348

349

350

351

352

Strategies for Enhancing Retention

- We will use strategies adapted from Madden et al to maximize participant retention. Key aspects of our retention strategies include:
 - The study visits are aligned with standard of care clinical visits for convenience
 - The study was designed to strike a balance between collecting sufficient information and not overburdening patients
 - Selection of clinical sites with experienced research personnel
 - The protocol allows for flexibility in visit windows to minimize missed visits
 - The methods centre will routinely monitor loss to follow-up and communicate with sites as needed
 - Research personnel will collect multiple pieces of contact information from participants



- We will request permission to access patients' medical records to identify all adverse events
 - Participants will only be deemed lost to follow-up until after the 6 month visit is due and after all exhaustive measures have been taken to locate the participant

Data Collection and Data Management

Clinical sites will be provided with the trial Case report forms (CRFs) prior to initiation of enrollment. Research personnel at each clinical site will submit the required data, as detailed on the CRFs, to the Methods Centre using the Research Electronic Data Capture (REDCap) system. Clinical site personnel will receive a unique login and password for the REDCap Cloud system and will be able to view and modify data for participants recruited at their clinical site. The REDCap Cloud system uses a variety of mechanisms for checking data at the time of entry including skip logic, range checks, and data type checks. Upon receipt of new data, the personnel at the Methods Centre will query all missing, implausible, or inconsistent data and clinical site personnel will be notified of open queries through regular quality control reports, and will be required to respond promptly. Methods Centre personnel will also conduct regular statistical monitoring of data, and periodic on-site and remote monitoring of data.

STATISTICAL METHODS

Sample Size

The sample size for the pilot trial is based primarily on feasibility objectives. We determined *a priori* that the study would be feasible if loss to follow-up is less than 10%. We believe that our loss to follow-up will be about 5%; therefore, using the confidence interval approach suggested by Thabane et al, we require 200 patients to achieve a 5% margin of error (which will generate a confidence interval that excludes 10%).

381 Statistical Principles

The analysis and reporting of results will follow the CONSORT guidelines for reporting of randomized pilot and feasibility trials. The process of participant enrolment and flow throughout the study will be summarized using a flow diagram. Participant demographics, medical history, surgical details, and peri-operative details will be summarized by treatment group using descriptive summary measures: expressed as mean, standard deviation and confidence



internvals (95%), or median and interquartile range for continuous variables, depending on the distribution, and number and percent for categorical variables. Statistical significance will be defined as a P value <0.05, and all statistical testing will be 2 – tailed. We plan to include the data from our pilot in the definitive trial if we are able to demonstrate feasibility and there are no important changes to our patient population, intervention, or outcome measures. All patients who are enrolled in the trial and randomized will be included in the analysis, regardless of level of adherence to the intervention, or any other deviation from protocol. We will not impute for missing data in this pilot trial.

395 396

387

388

389

390

391

392

393

394

Primary Analysis

- 397 Point estimates of recruitment and feasibility events, including adherence to protocol and follow-
- 398 up rate at one-year, as proportions with 95% CIs will be presented. The pilot study results will
- 399 be evaluated to identify recruitment issues, data management issues, and inform anticipated
- 400 follow-up rates.

401 402

Subgroup Analyses

- 403 We will not conduct any subgroup analyses in the pilot trial. If relevant, we may consider
- 404 subgroup analyses for the definitive trial.

405

406 Interim Analysis

- 407 We will not conduct an interim analysis for the pilot trial. We will not stop the trial for benefit,
- 408 and we will consider advice from the Data and Safety Monitoring Committee (DSMC) regarding
- 409 stopping for harm.

410 411

TRIAL ORGANIZATION

412 Principal Investigator

- 413 The Principal Investigator (PI) and Co-Principal Investigators (Co-PIs) are responsible for
- 414 overall study design and conduct. The Steering Committee, Advisory Cores, and DSMC will
- 415 provide advice to the PI and Co-PIs regarding trial design and conduct and the PI and Co-PIs
- 416 will be responsible for making decisions based on their advice. The PI and Co-PIs will also be
- 417 responsible for training and overseeing Methods Centre personnel, and ethics and regulatory
- 418 submissions.

419


420

Steering Committee and Advisory Cores



421 The Steering Committee and Advisory Cores are responsible for providing guidance and advice 422 regarding clinical, methodological, statistical, and practical aspects of the study design and 423 conduct. The Steering Committee will be comprised of a Steering Committee Chair, a Methods 424 Core, a Clinical Advisory Core, and a Patient Advisory Core. The Methods Core will consist of 425 methodologists and statisticians who will ensure scientific rigor of the trial. The Clinical Advisory 426 Core will consist of orthopaedic surgeons, pain experts, and other clinical experts as needed to 427 ensure applicability to the clinical areas of interest. The Patient Advisory Core will consist of at 428 least two patients who have experience with this type of injury to ensure applicability and 429 relevance to patients. 430 **Methods Centre** 431 432 The Methods Centre, under the direction of the Principal Investigator and Co-Principal 433 Investigators, are responsible for trial management, logistics, and execution. The Methods 434 Centre will be the primary correspondent between the PI/Co-PIs, clinical sites, and committees. 435 436 **Clinical Sites** 437 The clinical sites are responsible for screening, enrolling, randomizing, and following patients 438 according to the study protocol. They will also be responsible for communicating regularly with 439 the Methods Centre to resolve any data queries and quality control issues and communicate 440 adverse events in a timely manner. 441 442 443 444 **Data and Safety Monitoring Committee** 445 This trial will have a formal Data and Safety Monitoring Committee (DSMC) that is independent 446 of the study investigators. The DSMC's role is to regularly assess safety reports and the 447 progress of the trial and provide advice to the Principal Investigator and Steering Committee regarding continuation of the trial and other patient safety and data quality issues. The DSMC is 448 449 comprised of three members including a biostatistician (DSMB chair), a pain expert, and an 450 orthopaedic surgeon.





ETHICS AND DISSEMINATION

This study will be conducted according to international standards of ICH-GCP, applicable government regulations, and institutional research policies and procedures.

Research Ethics Approval

The Methods Center at McMaster University will receive ethics approval from the Hamilton Integrated Research Ethics Board (HiREB) prior to the distribution of this protocol and any approved study materials to participating clinical sites. Each participating site will also receive ethics approval prior to trial initiation.

Confidentiality

- Information about study participants will be kept confidential and managed in accordance with the following rules:
- All study-related information will be stored securely
- All study participant information will be stored in locked file cabinets within locked offices accessible only to study personnel
- All paper and electronic CRFs will be identified only by an anonymized participant ID code
- All study databases will be password-protected

Communication, transmission and storage of patient data will comply with the applicable ethics committee. In the event that a participant revokes authorization to collect or use personal health information, the participating clinical site retains the ability to use all information collected prior to the revocation of participant authorization. For participants who have revoked authorization to collect or use personal health information, attempts should be made to obtain permission to



478 collect at least vital status (i.e., primary outcome data) at the end of their scheduled study 479 period. 480 481 **Protocol Amendments** 482 Any amendments to the study protocol that may affect the conduct of the study or the potential 483 safety of, or benefits to, participants (e.g., changes to the study objectives, study design, sample 484 size, or study procedures) will require a formal amendment to the protocol. Any protocol 485 amendments will be approved by the Principal Investigator, the HiREB, local ethics committees 486 and funders (as needed). Participating clinical sites will also be required to submit amendment 487 requests to their local ethics committees to obtain approval for the amendment, and to provide 488 the Methods Centre with a copy of this approval. Administrative changes (e.g., minor 489 corrections or clarifications that have no effect on the way the study is conducted) will not need 490 to undergo a formal amendment process. 491 492 **Safety and Adverse Events** 493 Adverse Event Definition 494 An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in 495 severity during the course of the study. 496 497 Serious Adverse Event Definition 498 Adverse events are classified as serious or non-serious. A serious adverse event (SAE) is any 499 AE that meets at least one of the following criteria: 500 Fatal 501 Life-threatening 502 Requires or prolongs hospital stay Results in persistent or significant disability or incapacity 503 A congenital anomaly or birth defect 504 505 An important medical event 506 507 Unanticipated Problems Resulting in Risk to Participants or Others 508 Any incident, experience or outcome that meets all the following criteria should be considered 509 an unanticipated problem that results in risk to participants or others: 510 Unexpected in nature, severity, or frequency (e.g., not described in study-related 511 documents such as the ethics-approved protocol or Informed Consent Form, etc.);



- Related or possibly related to participation in research (i.e., possibly related means there
 is reasonable possibility that the incident, experience or outcome may have been caused
 by the procedures involved in the research); and
- Suggests that the research places participants or others at greater risk of harm (including physical, psychological, economic or social harm).

518

519

520

521

522

523

512

513

514

515

Unanticipated problems resulting in risk to participants or others encompass more than what one usually thinks of as AEs. 'Problems involving risk' may not necessarily result in harm. For example, misplacing a participant's study records containing identifiable private information introduces the risk of breach of confidentiality. Confidentiality may or may not be breached, but either way this would be a reportable event. Risks to other must also be reported. For example, an unexpected outburst during questionnaire administration by a study participant that put study personnel at risk would be a reportable event.

524525526

Clinical Site Reporting

- All AEs, SAEs, or unanticipated problems resulting in risk to participants or others are to be
- reported to the Methods Centre immediately. Participating clinical sites are responsible for
- reporting AEs and SAEs to the Methods Centre via the Adverse Event Form in the REDCap
- Cloud EDC system. The original Adverse Event Forms should be kept on file in the relevant
- participant's file. Significant new information on ongoing SAEs should also be promptly
- 532 provided to the Methods Centre via the REDCap Cloud EDC system. Unanticipated problems
- resulting in risk to participants or others are also to be promptly reported to the Methods Centre
- via telephone or email.

535536

537

538

539

540

Participating clinical sites are responsible for reporting SAEs and unanticipated problems resulting in risk to participants or others to their local ethics committee (such as an IRB or REB), or a central ethics committee, in accordance with local reporting requirements. Copies of each report and documentation of ethic committee notification and receipt will be kept in the participating clinical site's study file.

541542

Dissemination Policy

Results from the study will be submitted for publication regardless of whether or not there are significant findings. Every attempt will be made to ensure that the amount of time between completion of data collection and release of study findings is minimized. The Methods Centre



546 will also be responsible for reporting required results on clinicaltrials.gov or other applicable 547 clinical trials registry. 548 549 550 Acknowledgements 551 Thank you to the Centre for Evidence Based Orthopaedics for assisting in preparing this 552 553 protocol. 554 555 556 557 References 558 559

¹ Mock C, Cherian MN. The global burden of musculoskeletal injuries: challenges and solutions. Clin Orthop Relat Res. 2008 Oct;466(10):2306-16. Epub 2008 Aug 5.

² Agarwal-Harding, Kiran J., et al. "Estimating the global incidence of femoral fracture from road traffic collisions: a literature review." *JBJS* 97.6 (2015): e31.

³ O'Toole, Robert V., et al. "Resuscitation before stabilization of femoral fractures limits acute respiratory distress syndrome in patients with multiple traumatic injuries despite low use of damage control orthopedics." *Journal of Trauma and Acute Care Surgery* 67.5 (2009): 1013-1021.

⁴ Bouillon, B., et al. "Damage control orthopedics." *Der Unfallchirurg* 112.10 (2009): 860-869.

⁵ Pape, Hans-Christoph. "Effects of changing strategies of fracture fixation on immunologic changes and systemic complications after multiple trauma: damage control orthopedic surgery." *Journal of Orthopaedic Research* 26.11 (2008): 1478-1484.

⁶ Vallier, Heather A., et al. "Timing of orthopaedic surgery in multiple trauma patients: development of a protocol for early appropriate care." *Journal of orthopaedic trauma* 27.10 (2013): 543-551.

⁷ Canadian, Orthopaedic Trauma Society. "Nonunion following intramedullary nailing of the femur with and without reaming. Results of a multicenter randomized clinical trial." *The Journal of bone and joint surgery. American volume* 85.11 (2003): 2093.

⁸ Morshed, Saam, et al. "Delayed internal fixation of femoral shaft fracture reduces mortality among patients with multisystem trauma." *The Journal of Bone and Joint Surgery. American volume.* 91.1 (2009): 3.

- ⁹ Wolinsky, Philip R., et al. "Reamed intramedullary nailing of the femur: 551 cases." *Journal of Trauma and Acute Care Surgery* 46.3 (1999): 392-399.
- ¹⁰ Gausepohl, T., et al. "Antegrade femoral nailing: an anatomical determination of the correct entry point." *Injury* 33.8 (2002): 701-705.
- ¹¹ Firat, Ahmet, et al. "Surgical technique: supine patient position with the contralateral leg elevated for femoral intramedullary nailing." *Clinical Orthopaedics and Related Research*® 471.2 (2013): 640-648.
- ¹² Apostle, K. L., et al. "The effects of intraoperative positioning on patients undergoing early definitive care for femoral shaft fractures." *Journal of orthopaedic trauma* 23.9 (2009): 615-621.
- ¹³ Reahl, G. Bradley, et al. "Is Lateral Femoral Nailing Associated With Increased Intensive Care Unit Days? A Propensity-Matched Analysis of 848 Cases." *Journal of orthopaedic trauma* 32.1 (2018): 39-42.
- ¹⁴ Stephen, David JG, et al. "Femoral intramedullary nailing: comparison of fracture-table and manual traction: a prospective, randomized study." *JBJS* 84.9 (2002): 1514-1521.
- ¹⁵Femur fracture care frequent cause of lawsuit http://www2.aaos.org/bulletin/feb01/fline4.htm Online publication date, February 2001, AAOS bulletin. Date accessed: May 5th, 2018
- ¹⁶ Bråten M, Terjesen T, Rossvoll I. Torsional deformity after intramedullary nailing of femoral shaft fractures: measurement of anteversion angles in 110 patients. J Bone Joint Surg [Br] 1993;75-B:799-803.
- ¹⁷ Dougherty, Paul J. "CORR Insights®: Is the Lesser Trochanter Profile a Reliable Means of Restoring Anatomic Rotation After Femur Fracture Fixation?." *Clinical Orthopaedics and Related Research*® 476.6 (2018): 1262-1263.
- ¹⁸ Flierl, Michael A., et al. "Traction table-related complications in orthopaedic surgery." *JAAOS-Journal* of the American Academy of Orthopaedic Surgeons 18.11 (2010): 668-675.
- ¹⁹ Cost of orthopaedic fracture tables. Meditek product website. https://www.meditek.ca/much-orthopedic-surgery-table-cost-overview-fracture-trauma-tables/. Accessed May 8th, 2018.
- ²⁰ Carr, James B., Daniel Williams, and Mike Richards. "Lateral decubitus positioning for intramedullary nailing of the femur without the use of a fracture table." *Orthopedics* 32.10 (2009).
- ²¹ Reahl, G. Bradley, et al. "Is Lateral Femoral Nailing Associated With Increased Intensive Care Unit Days? A Propensity-Matched Analysis of 848 Cases." *Journal of orthopaedic trauma* 32.1 (2018): 39-42.
- ²² Stephen, David JG, et al. "Femoral intramedullary nailing: comparison of fracture-table and manual traction: a prospective, randomized study." *JBJS* 84.9 (2002): 1514-1521.
- ²³ The A-PREP and PREPARE Trials. https://www.prepittrial.com/aprep-trial-info/. Accessed May 25, 2019.